Randomized trial of adjuvant 5-FU-platinum vs paclitaxel-platinum for high-risk penile cancer
In brief
Paclitaxel-platinum halves grade 3-4 toxicities compared with 5-FU in node-positive penile cancer
In a small randomized trial of 49 men with high-risk node-positive penile SCC, paclitaxel-platinum caused severe toxicity in 41% versus 77% with 5-FU-platinum and patients completed more cycles (83% vs 48%). Disease-free and overall survival were similar, so larger studies are needed to confirm any efficacy advantage.
- Journal
- Journal of the National Cancer Institute (Q1)
- Published
- 24 August 2026
- Study design
- Randomized controlled trial
- Evidence level
- Level 1, High (CEBM 1b)
- Authors
- Vanita Noronha, Nandini Menon, Minit Shah, Vijay Patil, Aditya Dhanawat, Gagan Prakash, et al.
- PMID
- 42636270
- DOI
- 10.1093/jnci/djag288
Why clinicians should know about it
- Picked for Oncology and Radiation Oncology (top studies of the week, 18 October 2026): Randomized adjuvant 5‑FU vs paclitaxel in penile cancer
Abstract
BACKGROUND: Adjuvant chemotherapy is recommended for high-risk penile squamous cell carcinoma (SCC) metastatic to lymph nodes based on retrospective data, but no randomized trials have been conducted. We compared 5-fluorouracil (5-FU)-platinum with paclitaxel-platinum in this setting. METHODS: In this open-label, randomized trial at an Indian tertiary cancer center, men <70 years with resected node-positive penile SCC and ≥1 high-risk feature (perinodal extension, pelvic node involvement, >1 inguinal nodes, or ≥ 4 cm node) were assigned 1:1 to four 3-weekly cycles of 5-FU-platinum or paclitaxel-platinum, followed by cisplatin-based chemoradiotherapy. Primary endpoint was disease-free survival (DFS). Secondary endpoints were overall survival (OS), toxicity, and quality-of-life (QoL). RESULTS: Between 2017 and 2024, 49 patients were randomized (5-FU-platinum: 25, paclitaxel-platinum: 24). At a median follow-up of 69 months, median DFS was 12.4 months (95% CI, 3.38-NR) vs 19.6 months (95% CI, 5.82-NR) (HR, 1.16; 95% CI, 0.55-2.45; P = 0.686) and median OS was 21.3 vs 36.7 months (HR, 1.13; 95% CI, 0.52-2.44; P = 0.754) for 5-FU-platinum and paclitaxel-platinum, respectively. Grade ≥3 toxicities occurred in 77.3% vs 40.9% (P = 0.014), grade ≥3 hematologic toxicities in 54.5% vs 4.5% (P < 0.001), and hospitalization for toxicity in 45.5% vs 9.1% (P = 0.016). Completion of all planned cycles was higher with paclitaxel-platinum (83.3% vs 48%; P = 0.009). QoL and sexual health were similar between the two treatment arms. CONCLUSIONS: Adjuvant paclitaxel-platinum was associated with improved tolerability compared with fluorouracil-platinum in high-risk node positive penile cancer and warrants further evaluation in larger multicenter studies. Early termination precluded definitive efficacy comparisons. TRIAL REGISTRATION: Clinical Trials Registry of India (CTRI/2016/12/007567). FUNDING: This work was supported by Indian Cooperative Oncology Network and Tata Memorial Center.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.